Yuta Myojin

ミョウジンユウタ | Yuta Myojin

Affiliation and department：

Research field (1)： Gastroenterology

Research theme for competitive and other funds (2)：

2021 - 2023 癌微小環境において肝星細胞が肝癌細胞増殖に与える機序の解明
2019 - 2021 Liver cancer cells manipulate stromal cells involved in fibrosis to promote tumor growth

Papers (25)：

Shusuke Kumazaki, Hayato Hikita, Yuki Tahata, Ji Hyun Sung, Kenji Fukumoto, Yuta Myojin, Sadatsugu Sakane, Kazuhiro Murai, Yoichi Sasaki, Kumiko Shirai, et al. Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis. Alimentary pharmacology & therapeutics. 2024
Sadatsugu Sakane, Hayato Hikita, Kumiko Shirai, Tatsuya Sakamoto, Ryohei Narumi, Jun Adachi, Naruyasu Kakita, Yukinori Yamada, Hidenori Toyoda, Hirokazu Takahashi, et al. Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD. Hepatology communications. 2024. 8. 6
Kylynda C Bauer, Rajiv Trehan, Benjamin Ruf, Yuta Myojin, Mohamed-Reda Benmebarek, Chi Ma, Matthias Seifert, Amran Nur, Jonathan Qi, Patrick Huang, et al. The Gut Microbiome Controls Liver Tumors via the Vagus Nerve. bioRxiv : the preprint server for biology. 2024
Cecilia Monge, Changqing Xie, Yuta Myojin, Kelley L Coffman-D'Annibale, Donna Hrones, Gagandeep Brar, Sophie Wang, Anuradha Budhu, William D Figg, Maggie Cam, et al. Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma. Cancer medicine. 2024
Kelley Coffman-D'Annibale, Yuta Myojin, Cecilia Monge, Changqing Xie, Donna Mabry Hrones, Bradford J Wood, Elliot B Levy, David Kleiner, William Douglas Figg, Seth M Steinberg, et al. VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial. Journal for immunotherapy of cancer. 2024. 12. 1

ｍore...

MISC (41)：

Sadatsugu Sakane, Hayato Hikita, Kumiko Shirai, Ryohei Narumi, Jun Adachi, Ryotaro Sakamori, Naruyasu Kakita, Yukinori Yamada, Tatsuya Sakamoto, Machiko Kai, et al. SERUM Fibulin3 IS A NOVEL FIBROSIS MARKER IN NAFLD REVEALED BY PROTEOMIC ANALYSIS OF SERUM EXTRACELLULAR VESICLES. HEPATOLOGY. 2022. 76. S801-S801
Yuta Myojin, Hayato Hikita, Yuki Tahata, Akira Doi, Yoichi Sasaki, Kumiko Shirai, Sadatsugu Sakane, Ryoko Yamada, Takahiro Kodama, Ryotaro Sakamori, et al. GROWTH DIFFERENTIATION FACTOR 15 AS A NOVEL BIOMARKER FOR HEPATOCELLULAR CARCINOMA AFTER HCV ELIMINATION. HEPATOLOGY. 2021. 74. 543A-544A
Kenji Fukumoto, Hayato Hikita, Yoichi Sasaki, Seiya Kato, Yuta Myojin, Sadatsugu Sakane, Kazuhiro Murai, Yuki Makino, Takahiro Kodama, Ryotaro Sakamori, et al. SUPPRESSION OF MACROPHAGE AUTOPHAGY PROGRESSES THE PATHOLOGY OF NAFLD / NASH WITH CELLULAR SENESCENCE OF LSEC. HEPATOLOGY. 2021. 74. 1089A-1089A
小玉尚宏, 明神悠太, 村井大毅, 前阪和城, 山田涼子, 疋田隼人, 阪森亮太郎, 巽智秀, 竹原徹郎. 分子免疫プロファイルに基づいた肝細胞がんに対する薬物療法の治療戦略. 日本肝がん分子標的治療研究会プログラム・抄録集. 2021. 24th
村井一裕, 疋田隼人, 加藤聖也, 下田彬允, 工藤慎之輔, 福岡誠, 福富啓祐, 明神悠太, 佐藤克彦, 田畑優貴, et al. 慢性肝疾患患者における新型コロナウイルスIgG抗体陽性率の検討. 日本消化器病学会雑誌(Web). 2021. 118

ｍore...

Education (2)：

2016 - 2021 大阪大学大学院医学系研究科
2005 - 2011 Osaka University Faculty of Medicine Medical School

Professional career (2)：

Ph.D. (Osaka University)
M.D. (Osaka University)

Work history (3)：

2021/07 - 現在 National Cancer Institute Visiting Fellow
2015/04 - 2021/07 大阪大学大学院医学系研究科消化器内科学医員
2011/04 - 2015/03 関西労災病院医員

Awards (8)：

2021/12 - 第6回Gastro-PLUS 優秀賞
2021/11 - 日本消化器関連学会機構若手奨励賞
2021/11 - 日本肝臓学会冠アワード(Abbvie Award)
2021/09 - Japanese Cancer Association The Young Investigator Awards of the Japanese Cancer Association
2020/11 - The Liver Meeting® Digital Experience (TLMdX) Early Career Investigator Award in Basic Science

Show all

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page